Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-27T04:28:02.319Z Has data issue: false hasContentIssue false

Chapter 11 - Medication and nutritional treatments for children with ASDs

from Section 2 - Assessing and Treating Children with Autism Spectrum Disorders

Published online by Cambridge University Press:  05 November 2012

Mark Reber
Affiliation:
Drexel University, Philadelphia
Get access

Summary

Generally speaking, the goal of medication treatment in autism is to ameliorate symptoms or symptom domains, such as compulsive behaviors, hyperactivity, mood disturbance, and temper outbursts that can interfere with an individual’s development and learning. At present there are no standard medications that effectively treat major core symptoms of autism – the social deficits, speech and language abnormalities, and restricted interests that define the ASDs. As suggested in previous chapters, core symptoms are best approached with educational, behavioral, and habilitative interventions. This chapter will review the research on pharmacologic treatment of specific symptom domains associated with autism. Based on this research and on clinical experience, recommendations will be made with regard to ways in which medications can best be used to treat children with these symptoms.

The chapter will conclude with a discussion of pharmacotherapy and nutritional interventions from the realm of complementary and alternative medicine. These treatments are rarely symptom-specific, and advocates for their use sometimes claim a broader aim: to reverse core symptoms or even “cure” autism.

Type
Chapter
Information
The Autism Spectrum
Scientific Foundations and Treatment
, pp. 258 - 284
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Akins, R. S.Angkustsiri, K.Hansen, R. L. 2010 Complementary and alternative medicine in autism: an evidence-based approach to negotiating safe and efficacious interventions with familiesNeurotherapeutics 7 301CrossRefGoogle ScholarPubMed
Aman, M. G.Singh, N. N.Stewart, A. W. 1985 Psychometric characteristics of the Aberrant Behavior ChecklistAm J Ment Defic 89 492Google ScholarPubMed
American Psychiatric Associationhttp://www.psych.org/MainMenu/Research/DSMIV/DSMV/DSMRevisionActivities/DSMVWorkGroupReports/NeurodevelopmentalDisordersWorkGroupReport.aspx
Amminger, G. P.Berger, G. E.Schäfer, M. R. 2007 Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot studyBiol Psychiatry 61 551CrossRefGoogle ScholarPubMed
Anderson, L. TCampbell, M.Adams, P. 1989 The effects of haloperidol on discrimination learning and behavioral symptoms in autistic childrenJ Autism Dev Disord 19 227CrossRefGoogle ScholarPubMed
Anderson, L. T.Campbell, M.Grega, D. M. 1984 Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptomsAm J Psychiatry 141 1195Google ScholarPubMed
Arnold, L. E.Aman, M. G.Cook, A. M. 2006 Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trialJ Am Acad Child Adolesc Psychiatry 45 1196CrossRefGoogle ScholarPubMed
Belsito, K. M.Law, P. A.Kirk, K. S. 2001 Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trialJ Autism Dev Disord 31 175CrossRefGoogle ScholarPubMed
Bent, S.Bertoglio, K.Hendren, R. L. 2009 Omega-3 fatty acids for autistic spectrum disorder: a systematic reviewJ Autism Dev Disord 39 1145CrossRefGoogle ScholarPubMed
Bent, S.Bertoglio, K.Ashwood, P. 2011 A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorderJ Autism Dev Disord 41 545CrossRefGoogle ScholarPubMed
Bertoglio, K.James, S. J.Deprey, L. 2010 Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autismJ Altern Complement Med 16 555CrossRefGoogle ScholarPubMed
Bolman, W. M.Richmond, J. A. 1999 A double-blind, placebo-controlled crossover pilot trial of low dose dimethylglycine in patients with autistic disorderJ Autism Dev Disord 29 191CrossRefGoogle ScholarPubMed
Brodkin, E. S.McDougle, C. J.Naylor, S. T. 1997 Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigationJ Child Adolesc Psychopharmacol 7 109CrossRefGoogle ScholarPubMed
Brudnak, M. A.Rimland, B.Kerry, R. E. 2002 Enzyme-based therapy for autism spectrum disorders – is it worth another look?Med Hypotheses 58 422CrossRefGoogle ScholarPubMed
Campbell, M.Anderson, L. T.Meier, M. 1978 A comparison of haloperidol and behavior therapy and their interaction in autistic childrenJ Am Acad Child Adolesc Psychiatry 17 640CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention (CDC) 2006 Deaths associated with hypocalcemia from chelation therapy – Texas, Pennsylvania, and Oregon, 2003–2005MMWR Morb Mortal Wkly Rep 55 204Google Scholar
Charlton, C. G.O’Donohue, T. L.Miller, R. L. 1981 Secretin immunoreactivity in rat and pig brainPeptides 2 45CrossRefGoogle ScholarPubMed
Chez, M. G.Buchanan, C. P.Aimonovitch, M. C. 2002 Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disordersJ Child Neurol 17 833CrossRefGoogle ScholarPubMed
Cook, Jr., E. H.Rowlett, R.Jaselskis, C. 1992 Fluoxetine treatment of children and adults with autistic disorder and mental retardationJ Am Acad Child Adolesc Psychiatry 31 739CrossRefGoogle ScholarPubMed
Coplan, J. 2010 Making Sense of Autistic Spectrum DisordersNew York, NYBantam BooksGoogle Scholar
Corbett, B.Khan, K.Czapansky-Beilman, D. 2001 A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autismClin Pediatr 40 327CrossRefGoogle ScholarPubMed
Couturier, J. L.Nicolson, R. 2002 A retrospective assessment of citalopram in children and adolescents with pervasive developmental disordersJ Child Adolesc Psychopharmacol 12 243CrossRefGoogle ScholarPubMed
Corson, A. H.Barkenbus, J. E.Posey, D. J. 2004 A retrospective analysis of quetiapine in the treatment of pervasive developmental disordersJ Clin Psychiatry 65 1531CrossRefGoogle ScholarPubMed
DelGiudice-Asch, G.Simon, L.Schmeidler, J. 1999 Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autismJ Autism Dev Disord 29 157CrossRefGoogle ScholarPubMed
Delong, G. R.Ritch, C. R.Burch, S. 2002 Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievementDev Med Child Neurol 44 652CrossRefGoogle ScholarPubMed
Dolske, M. C.Spollen, J.McKay, S. 1993 A preliminary trial of ascorbic acid as supplemental therapy for autismProg Neuropsychopharmacol Biol Psychiatry 17 765CrossRefGoogle ScholarPubMed
Elder, J. H.Shankar, M.Shuster, J. 2006 The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trialJ Autism Dev Disord 36 413CrossRefGoogle ScholarPubMed
Esbensen, A. J.Greenberg, J. S.Seltzer, M. M. 2009 A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autistic spectrum disordersJ Autism Dev Disord 39 1339CrossRefGoogle Scholar
Fankhauser, M. P.Karumanchi, V. C.German, M. L. 1992 A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autismJ Clin Psychiatry 53 77Google ScholarPubMed
Feasby, T.Banwell, B.Benstead, T. 2007 Guidelines on the use of intravenous immune globulin for neurologic conditionsTransfus Med Rev 21 S57CrossRefGoogle ScholarPubMed
Filipek, P. A.Juranek, J.Nguyen, M. T. 2004 Relative carnitine deficiency in autismJ Autism Dev Disord 34 615CrossRefGoogle Scholar
Findling, R. L.McNamara, N. K.Gracious, B. L. 2004 Quetiapine in nine youths with autistic disorderJ Child Adolesc Psychopharmacol 14 287CrossRefGoogle ScholarPubMed
Gordon, C. T.State, R. C.Nelson, J. E. 1993 A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorderArch Gen Psychiatry 50 441CrossRefGoogle ScholarPubMed
Handen, B. L.Johnson, C. R.Lubetsky, M. 2000 Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorderJ Autism Dev Disord 30 245CrossRefGoogle ScholarPubMed
Handen, B. L.Sahl, R.Hardan, A. Y. 2008 Guanfacine in children with autism and/or intellectual disabilitiesJ Dev Behav Pediatr 29 303CrossRefGoogle Scholar
Handen, B. L.Melmed, R. D.Hansen, R. L. 2009 A double-blind, placebo-controlled trial of oral immunoglobulin for gastrointestinal dysfunction in children with autistic disorderJ Autism Dev Disord 39 796CrossRefGoogle ScholarPubMed
Hardan, A. Y.Jou, R. J.Handen, B. L. 2004 A retrospective assessment of topiramate in children and adolescents with pervasive developmental disordersJ Child Adolesc Psychopharmacol 14 426CrossRefGoogle ScholarPubMed
Hardan, A. Y.Jou, R. J.Handen, B. L. 2005 Retrospective study of quetiapine in children and adolescents with pervasive developmental disordersJ Autism Dev Disord 35 387CrossRefGoogle ScholarPubMed
Hellings, J. A.Weckbaugh, M.Nickel, E. J. 2005 A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disordersJ Child Adolesc Psychopharmacol 15 682CrossRefGoogle ScholarPubMed
Hollander, E.Chaplin, W.Soorya, L. 2010 Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disordersNeuropsychopharmacology 35 990CrossRefGoogle ScholarPubMed
Hollander, E.Phillips, A.Chaplin, W. 2005 A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autismNeuropsychopharmacology 30 582CrossRefGoogle ScholarPubMed
Hollander, E.Soorya, L.Wasserman, S. 2006 Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorderInt J Neuropsychopharmacol 9 209CrossRefGoogle ScholarPubMed
Hollander, E.Wasserman, S.Swanson, E. N. 2006 A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorderJ Child Adolesc Psychopharmacol 16 541CrossRefGoogle ScholarPubMed
Hollway, J. A.Aman, M. G. 2011 Sleep correlates of pervasive developmental disorders: a review of the literatureRes Dev Disabil 32 1399CrossRefGoogle ScholarPubMed
Horvath, K.Stefanatos, G.Sokolski, K. N. 1998 Improved social and language skills after secretin administration in patients with autistic spectrum disordersJ Assoc Acad Minor Phys 9 9Google ScholarPubMed
Huffman, L. C.Sutcliffe, T. L.Tanner, I. S. D. 2011 Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary–alternative medicine treatmentsJ Dev Behav Pediatr 32 56CrossRefGoogle ScholarPubMed
Hyman, S. L.Levy, S. E. 2011 Dietary, complementary and alternative therapiesReichow, B.Doehring, P.Cicchetti, D. V.Evidence-based Practices and Treatments for Children with Autism275New York, NYSpringerCrossRefGoogle Scholar
James, S. J.Melnyk, S.Fuchs, G. 2009 Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autismAm J Clin Nutr 89 425CrossRefGoogle ScholarPubMed
Jankovic, J.Jimenez-Shahed, J.Brown, L. W. 2010 A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndromeJ Neurol Neurosurg Psychiatry 81 70CrossRefGoogle ScholarPubMed
Jaselskis, C. A.CookJr., E. H.Fletcher, K. E. 1992 Clonidine treatment of hyperactive and impulsive children with autistic disorderJ Clin Psychopharmacol 5 322Google Scholar
Johnson, K. P.Giannotti, F.Cortesi, F. 2009 Sleep patterns in autism spectrum disordersChild Adolesc Psychiatric Clin N Am 18 917CrossRefGoogle ScholarPubMed
Kemner, C.Willemsen-Swinkels, S. H.de Jonge, M. 2002 Open-label study of olanzapine in children with pervasive developmental disorderJ Clin Psychopharmacol 22 455CrossRefGoogle ScholarPubMed
Kern, J. K.Miller, V. S.Cauller, L. 2001 Effectiveness of N, N-dimethylglycine in autism and pervasive developmental disorderJ Child Neurol 16 169CrossRefGoogle ScholarPubMed
Kern, J. K.Van Miller, S.Evans, P. A. 2002 Efficacy of porcine secretin in children with autism and pervasive developmental disorderJ Autism Dev Disord 32 153CrossRefGoogle ScholarPubMed
King, B. H.Hollander, E.Sikich, L. 2009 Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autismArch Gen Psychiatry 66 583CrossRefGoogle Scholar
Knivsberg, A. M.Reichelt, K. L.Høien, T. 2002 A randomised, controlled study of dietary intervention in autistic syndromesNutr Neurosci 5 251CrossRefGoogle ScholarPubMed
Langworthy-Lam, K. S.Aman, M. G.Van Bourgondien, M. E. 2002 Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North CarolinaJ Child Adolesc Psychopharmacol 12 311CrossRefGoogle ScholarPubMed
Levy, S. E.Mandell, D. S.Merhar, S. 2003 Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorderJ Dev Behav Pediatr 24 418CrossRefGoogle ScholarPubMed
Levy, S. E.Souders, M. C.Wray, J. 2003 Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretinArch Dis Child 88 731CrossRefGoogle ScholarPubMed
Levy, S. E.Hyman, S. L. 2005 Novel treatments for autistic spectrum disordersMent Retard Dev Disabil Res Rev 11 131CrossRefGoogle ScholarPubMed
Lewis, M. H.Bodfish, J. W. 1998 Repetitive behavior disorders in autismMent Retard Dev Disabil Res Rev 4 803.0.CO;2-0>CrossRefGoogle Scholar
Mandell, D. S.Morales, K. H.Marcus, S. C. 2008 Psychotropic medication use among Medicaid-enrolled children with autism spectrum disordersPediatrics 121 e441CrossRefGoogle ScholarPubMed
Malone, R. P.Cater, J.Sheikh, R. M. 2001 Olanzapine versus haloperidol in children with autistic disorder: an open pilot studyJ Am Acad Child Adolesc Psychiatry 40 887CrossRefGoogle Scholar
Malone, R. P.Delaney, M. A.Hyman, S. B. 2007 Ziprasidone in adolescents with autism: an open-label pilot studyJ Child Adolesc Psychopharmacol 17 779CrossRefGoogle ScholarPubMed
Marcus, R. N.Owen, R.Kamen, L. 2009 A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorderJ Am Acad Child Adolesc Psychiatry 48 1110CrossRefGoogle ScholarPubMed
Martin, A.Koenig, K.Scahill, L. 1999 Open-label quetiapine in the treatment of children and adolescents with autistic disorderJ Child Adolesc Psychopharmacol 9 99CrossRefGoogle ScholarPubMed
Martin, A.Koenig, K.Anderson, G. M. 2003 Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label studyJ Autism Dev Disord 33 77CrossRefGoogle ScholarPubMed
Masi, G.Cosenza, A.Millepiedi, S. 2009 Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective studyCNS Drugs 23 511CrossRefGoogle Scholar
McCracken, J. T.McGough, J.Shah, B. 2002 Risperidone in children with autism and serious behavioral problemsN Engl J Med 347 314CrossRefGoogle ScholarPubMed
McDougle, C. J.Brodkin, E. S.Naylor, S. T. 1998 Sertraline in adults with pervasive developmental disorders: a prospective open-label investigationJ Clin Psychopharmacol 18 62CrossRefGoogle ScholarPubMed
McDougle, C. J.Kem, D. L.Posey, D. J. 2002 Case series: use of ziprasidone for maladaptive symptoms in youths with autismJ Am Acad Child Adolesc Psychiatry 41 921CrossRefGoogle ScholarPubMed
McDougle, C. J.Kresch, L. E.Posey, D. J. 2000 Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitorsJ Autism Dev Disord 30 427CrossRefGoogle ScholarPubMed
McDougle, C. J.Naylor, S. T.Cohen, D. J. 1996 A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorderArch Gen Psychiatry 53 1001CrossRefGoogle Scholar
McDougle, C. J.Scahill, L.Aman, M. G. 2005 Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric PsychopharmacologyAm J Psychiatry 162 1142CrossRefGoogle Scholar
Meiri, G.Bichovsky, Y.Belmaker, R. H. 2009 Omega 3 fatty acid treatment in autismJ Child Adolesc Psychopharmacol 19 449CrossRefGoogle ScholarPubMed
Ming, X.Gordon, E.Kang, N. 2008 Use of clonidine in children with autism spectrum disordersBrain Dev 30 454CrossRefGoogle ScholarPubMed
Molloy, C. A.Manning-Courtney, PSwayne, S. 2002 Lack of benefit of intravenous synthetic human secretin in the treatment of autismJ Autism Dev Disord 32 545CrossRefGoogle ScholarPubMed
Moretti, P.Sahoo, T.Hyland, K. 2005 Cerebral folate deficiency with developmental delay, autism, and response to folinic acidNeurology 64 1088CrossRefGoogle ScholarPubMed
Murray, M. J. 2010 Attention-deficit/hyperactivity disorder in the context of autism spectrum disordersCurrent Psychiatry Rep 12 382CrossRefGoogle Scholar
Namerow, L. B.Thomas, P.Bostic, J. Q. 2003 Use of citalopram in pervasive developmental disordersJ Dev Behav Pediatr 24 104CrossRefGoogle ScholarPubMed
Niederhofer, H.Staffen, W.Mair, A. 2003 Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorderNeuropsychopharmacology 28 1014CrossRefGoogle ScholarPubMed
Nye, C.Brice, A. 2005 Combined vitamin B6–magnesium in autism spectrum disorderCochrane Database Syst Rev 19 CD003497Google Scholar
Owen, R.Sikich, L.Marcus, R. N. 2009 Aripiprazole in the treatment of irritability in children and adolescents with autistic disorderPediatrics 124 1533CrossRefGoogle ScholarPubMed
Owens, J. A.Moturi, S. 2009 Pharmacologic treatment of pediatric insomniaChild Adolesc Psychiatr Clin N Am 18 1001CrossRefGoogle ScholarPubMed
Owley, T.McMahon, W.Cook, E. H. 2001 Multisite, double-blind, placebo-controlled trial of porcine secretin in autismJ Am Acad Child Adolesc Psychiatry 40 1293CrossRefGoogle ScholarPubMed
Owley, T.Walton, L.Salt, J. 2005 An open-label trial of escitalopram in pervasive developmental disordersJ Am Acad Child Adolesc Psychiatry 44 343CrossRefGoogle ScholarPubMed
Pandina, G. J.Bossie, C. A.Youssef, E. 2007 Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trialJ Autism Dev Disord 37 367CrossRefGoogle Scholar
Perry, R.Campbell, M.Adams, P. 1989 Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administrationJ Am Acad Child Adolesc Psychiatry 28 87CrossRefGoogle ScholarPubMed
Posey, D. J.Aman, M. G.McCracken, J. T. 2007 Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measuresBiol Psychiatry 61 538CrossRefGoogle ScholarPubMed
Posey, D. J.Erickson, C. A.Stigler, K. A. 2006 The use of selective serotonin reuptake inhibitors in autism and related disordersJ Child Adolesc Psychopharmacol 16 181CrossRefGoogle ScholarPubMed
Posey, D. J.Puntney, J. I.Sasher, T. M. 2004 Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 casesJ Child Adolesc Psychopharmacol 14 233CrossRefGoogle ScholarPubMed
Posey, D. J.Stigler, K. A.Erickson, C. A. 2008 Antipsychotics in the treatment of autismJ Clin Invest 118 6CrossRefGoogle ScholarPubMed
Posey, D. J.Wiegand, R. E.Wilkerson, J. 2006 Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disordersJ Child Adolesc Psychopharmacol 16 599CrossRefGoogle ScholarPubMed
Potenza, M. N.Holmes, J. P.Kanes, S. J. 1999 Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot studyJ Clin Psychopharmacol 19 37CrossRefGoogle ScholarPubMed
Quintana, H.Birmaher, B.Stedge, D. 1995 Use of methylphenidate in the treatment of children with autistic disorderJ Autism Dev Disord 25 283CrossRefGoogle ScholarPubMed
Remington, G.Sloman, L.Konstantareas, M. 2001 Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover studyJ Clin Psychopharmacol 21 440CrossRefGoogle ScholarPubMed
Research Units on Pediatric Psychopharmacology Autism Network 2005 Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 monthsAm J Psychiatry 162 1361CrossRefGoogle Scholar
Research Units on Pediatric Psychopharmacology Autism Network 2005 Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivityArch Gen Psychiatry 62 1266CrossRefGoogle Scholar
Rey, J. M.Walter, G.Soh, N. 2008 Complementary and alternative medicine (CAM) treatments and pediatric psychopharmacologyJ Am Acad Child Adoles Psychiatry 47 364CrossRefGoogle ScholarPubMed
Rezaei, V.Mohammadi, M. R.Ghanizadeh, A. 2010 Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorderProg Neuropsychopharmacol Biol Psychiatry 34 1269CrossRefGoogle ScholarPubMed
Roberts, W.Weaver, L.Brian, J. 2001 Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo- controlled trialPediatrics 107 E71CrossRefGoogle ScholarPubMed
Rosenberg, R. E.Mandell, D. S.Farmer, J. E. 2010 Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007–2008J Autism Dev Disord 40 342CrossRefGoogle Scholar
Sahley, T. L.Panksepp, J. 1987 Brain opioids and autism: an updated analysis of possible linkagesJ Autism Dev Disord 17 201CrossRefGoogle ScholarPubMed
Sanchez, L. E.Campbell, M.Small, A. M. 1996 A pilot study of clomipramine in young autistic childrenJ Am Acad Child Adolesc Psychiatry 35 537CrossRefGoogle ScholarPubMed
Sandler, A. D.Sutton, K. A.DeWeese, J. 1999 Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorderN Engl J Med 341 1801CrossRefGoogle ScholarPubMed
Scahill, L.Aman, M. G.McDougle, C. J. 2006 A prospective open trial of guanfacine in children with pervasive developmental disordersJ Child Adolesc Psychopharmacol 16 589CrossRefGoogle ScholarPubMed
Shea, S.Turgay, A.Carroll, A. 2004 Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disordersPediatrics 114 e634CrossRefGoogle ScholarPubMed
South, M.Ozonoff, S.McMahon, W. M. 2005 Repetitive behavior profiles in Asperger syndrome and high-functioning autismJ Autism Dev Disord 35 145CrossRefGoogle ScholarPubMed
Sponheim, E.Oftedal, G.Helverschou, S. B. 2002 Multiple doses of secretin in the treatment of autism: a controlled studyActa Paediatr 91 540CrossRefGoogle ScholarPubMed
Steingard, R. J.Zimnitzky, B.DeMaso, D. R. 1997 Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorderJ Child Adolesc Psychopharmacol 7 9CrossRefGoogle ScholarPubMed
Stigler, K. A.Diener, J. T.Kohn, A. E. 2009 Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 14-week, prospective, open-label studyJ Child Adolesc Psychopharmacol 19 265CrossRefGoogle Scholar
Stigler, K. A.Posey, D. J.McDougle, C. J. 2004 Aripiprazole for maladaptive behavior in pervasive developmental disordersJ Child Adolesc Psychopharmacol 14 455CrossRefGoogle ScholarPubMed
Sugie, Y.Sugie, H.Fukuda, T. 2005 Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autismJ Autism Dev Disord 35 377CrossRefGoogle Scholar
Troost, P. W.Steenhuis, M. P.Tuynman-Qua, H. G. 2006 Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot studyJ Child Adolesc Psychopharmacol 16 611CrossRefGoogle ScholarPubMed
Turner, M. A. 1999 Annotation: Repetitive behaviour in autism: a review of psychological researchJ Child Psychol Psychiatry 40 839CrossRefGoogle ScholarPubMed
Valicenti-McDermott, M. R.Demb, H. 2006 Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilitiesJ Child Adolesc Psychopharmacol 16 549CrossRefGoogle ScholarPubMed
Wasdell, M. B.Jan, J. E.Bomben, M. M. 2008 A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilitiesJ Pineal Res 44 57Google Scholar
Wasserman, S.Iyengar, R.Chaplin, W. F. 2006 Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled studyInt Clin Psychopharmacol 21 363CrossRefGoogle ScholarPubMed
White, J. F. 2003 Intestinal pathophysiology in autismExp Biol Med (Maywood) 228 639CrossRefGoogle Scholar
Williams, K. J.Wray, J. J.Wheeler, D. M. 2005 Intravenous secretin for autism spectrum disorderCochrane Database Syst Rev 3 CD003495Google Scholar
Wirojanan, J.Jacquemont, S.Diaz, R. 2009 The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndromeJ Clin Sleep Med 5 145Google ScholarPubMed
Wright, B.Sims, D.Smart, S. 2011 Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomized controlled crossover trialJ Autism Dev Disord 41 175CrossRefGoogle ScholarPubMed
Zeiner, P.Gjevik, E.Weidle, B. 2011 Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorderActa Paediatr 100 1258CrossRefGoogle ScholarPubMed
Zimmer, M.Molloy, C. A. 2007 Complementary and alternative therapies for autismHollander, E.Anagnostou, E.Clinical Manual for the Treatment of AutismArlington, VAAmerican Psychiatric Publishing, IncGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×